Clinique du motoneurone

University Hospital Gui de Chauliac

The Montpellier ALS center is the referral center for the French region Occitania, a 5.8 Million people area

Clinique du motoneurone_logopng
University Hospital Gui de Chauliac

The Montpellier ALS center is included in the Department of Neurology of the University Hospital Gui de Chauliac, and is headed by Prof. Dr. William Camu. Established in 1988, the center obtained the national label of ALS center by the Ministry of Health in 2003. On a regular basis, between 500 and 600 patients with motor neuron diseases are in care. Research aspects of the center include epidemiology, phenotype, genetics, biomarkers and clinical trials. The center has participated in all the major trials in ALS since 1989, and conducted a series of pilot trials in ALS. Through national and international collaborations, more than 200 papers have been published by the center in referenced journals.

Contact
Location
Clinique du motoneurone, CHU Gui de Chauliac, 34295, Montpellier Cedex 5, France

Our specialists

William Camu

Professor of Neurology

Dr William Camu graduated as an MD and specialist in Neurology in […]

William Camu
Trials
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
Read more
Active
Phase iii

ALXN1210-ALS-308 trial

Industry trial
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Read more
Active
Phase iii

VALOR study

Industry trial
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more